<span id="midArticle_start"/> (Reuters) - Supersonic Imagine SA :
<span id="midArticle_0"/>* Announces clinical data from its retrospective multicenter trial evaluating ShearWave elastography for the non-invasive staging of patients with chronic liver disease
<span id="midArticle_1"/>* SWE demonstrated robust sensitivity and specificity across all forms of liver disease
<span id="midArticle_2"/>* Results revealed ability to accurately evaluate liver disease caused by hepatitis C, hepatitis B and non-alcoholic fatty liver disease including NASH (non-alcoholic steatohepatitis)
<span id="midArticle_3"/>* Primary endpoint of this trial was overall performance of SWE measured as area-under-receiver-operating-characteristic curves Source text for Eikon: Further company coverage: (Gdynia Newsroom:)
<span id="midArticle_4"/>
<span id="midArticle_0"/>* Announces clinical data from its retrospective multicenter trial evaluating ShearWave elastography for the non-invasive staging of patients with chronic liver disease
<span id="midArticle_1"/>* SWE demonstrated robust sensitivity and specificity across all forms of liver disease
<span id="midArticle_2"/>* Results revealed ability to accurately evaluate liver disease caused by hepatitis C, hepatitis B and non-alcoholic fatty liver disease including NASH (non-alcoholic steatohepatitis)
<span id="midArticle_3"/>* Primary endpoint of this trial was overall performance of SWE measured as area-under-receiver-operating-characteristic curves Source text for Eikon: Further company coverage: (Gdynia Newsroom:)
<span id="midArticle_4"/>
via Smart Health Shop Forum http://ift.tt/1zbbwgA
No comments:
Post a Comment